IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic…
Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC) Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced significant updates to two mission-driven initiatives:…
Osmo, the Olfactory Technology Company, Opens New Headquarters and Manufacturing Facility in Elizabeth, New Jersey Osmo, the olfactory technology company, marked the opening of its 60,000-square-foot manufacturing facility in Elizabeth, New Jersey. The facility, where Osmo will expand the commercialization…
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active…
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company…
Chemical Reduction Solutions LLC Expands Partnership with Simoniz USA Inc. to Exclusively Commercialize Nanobubble Technology in the Car Wash Industry Chemical Reduction Solutions LLC (“CRS”), a developer of hydrodynamic cavitation-based nanobubble technology, today announced an expanded partnership with Simoniz USA…
TRUQAP® (capivasertib)recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy…
Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials Sunnybrook Health Sciences Centre is proud to announce a $41M philanthropic investment in Sunnybrook Clinical Trials. The investment expands dedicated infrastructure, capacity and expertise across Sunnybrook to optimize how clinical…
Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions Integrated DNA Technologies a Danaher company and a global leader in genomics, announced the expansion of its manufacturing footprint in Coralville, Iowa. The investment delivers a…
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, announced that the…
OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform OncoNano Medicine, Inc. a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, announced it will present new preclinical data at the…
Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify pathogens and…